The common metastatic sites of ovarian malignant germ cell tumors are the pelvis, abdominal peritoneum, greater omentum, appendix, pelvic lymph nodes, and para-aortic lymph nodes, etc. Except for asexual cell tumors, the contralateral ovary and uterus are less frequently involved, so the international staging is based on tumor invasion in these sites to guide treatment and understand prognosis. Some scholars believe that tumor staging is an independent factor affecting recurrence and prognosis. Kumar et al. analyzed 613 patients who underwent lymph node dissection MOGCT, and the incidence of lymphatic metastasis was 18.1%, among which 28% of asexual cell tumors showed lymphatic metastasis. The prognosis of the lymph node metastasis group was worse than that of the non-metastatic group, pointing to lymph node metastasis as an independent factor in reducing survival and emphasizing the value of para-aortic lymph node dissection. However, systemic lymph node dissection combined with large omental resection and multi-point peritoneal biopsy for comprehensive staging is more invasive and carries increased risks, and the long postoperative recovery time affects the timing of adjuvant chemotherapy, and pelvic adhesions can be detrimental to fertility. Although a large number of retrospective studies have shown that the thoroughness of surgery is an independent factor affecting prognosis, malignant germ cell tumors of the ovary are very sensitive to chemotherapy, and the treatment plan should take into account the combination of treatment and the patient’s needs, rather than only pursuing the thoroughness of surgery. In a retrospective analysis of 26 patients with clinical stage Ia asexual cell tumors, Mangili [[ii]] et al. showed an overall recurrence rate of 11.5%, all of which occurred in patients without full staging, and all recurrent patients achieved remission with remedial therapy, suggesting that re-staging surgery or observation is feasible in patients without full staging at first treatment, and that recurrent patients can achieve better outcomes with chemotherapy. In contrast, Weinberg [7] et al. reported that among 40 patients with MOGCT, all three cases of recurrence were those who underwent full-stage surgery and were cured after surgery and chemotherapy, and concluded that the recurrence rate and survival rate were not affected by staging surgery. Therefore, the NCCN (2013) guidelines suggest that for patients with incomplete staging at the initial surgery, if the pathology is stage I asexual cell tumor or stage I G1 immature teratoma, close observation may be chosen, and other stages may be combined with chemotherapy after restaging surgery. Other pathological types may be treated directly with chemotherapy without restaging surgery.